The Use of Predictive or Prognostic Genetic Biomarkers in Endometrial and Other Hormone-Related Cancers: Justification for Extensive Candidate Gene Single Nucleotide Polymorphism Studies of the Matrix Metalloproteinase Family and their Inhibitors

O’Mara, Tracy A.; Clements, Judith A.; Spurdle, Amanda B.

doi:10.1158/1055-9965.epi-08-1184

Cited by 17 publications

(14 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is generally believed that the development of the invasive phenotype (advanced metastatic stage of cancer) and further poor prognosis may be associated with increased expression of MMPs [22, 24, 25]. Furthermore, we know that MMPs regulatory effect may be related to MMP promoter SNPs.…”

Section: Discussionmentioning

confidence: 99%

MMP7 and MMP8 genetic polymorphisms in bladder cancer patients

Wieczorek

Reszka

Wąsowicz

et al. 2013

CEJU

View full text Add to dashboard Cite

IntroductionBreakdown of the extracellular matrix by matrix metalloproteinases (MMPs), as we know, is one of mechanisms involved and required in tumor invasion. MMP7 is a negative prognostic factor of various malignances, while MMP8 exhibits an inhibitory effect on tumorigenesis and metastasis. We evaluated the potential association of functional polymorphisms in the promoter of the MMP7 (rs11568818) and MMP8 (rs11225395) genes and bladder cancer (BCa) risk.Materials and methodsThe study included 241 BCa cases and 199 healthy population controls that were collected at the First Department of Urology, Medical University (Łódź, Poland) and at the Nofer Institute of Occupational Medicine (Łódź, Poland). Genomic DNA samples were isolated from venous blood and genetic polymorphisms were analyzed by real–time polymerase chain reaction using TaqMan fluorescent probes. Associations between genotype and allele status were estimated by logistic regression models adjusted for classic risk factors (e.g. age, gender and cigarette smoking).ResultsMMP7 and MMP8 genotypes were distributed similarly in BCa patients and in controls and at least one variant allele was not associated with BCa cancer risk (OR, 0.91; 95% CI, 0.60–1.39; p = 0.662 for MMP7 and OR, 0.96; 95% CI, 0.63–1.46; p = 0.836 for MMP8). We observed higher prevalence of MMP7 GG genotypes among BCa patients than in controls (OR, 1.54; 95% CI, 0.93–2.55; p = 0.093). Additionally, genetic polymorphisms in the MMP7 and MMP8 were not associated with the tumor grade or stage.ConclusionsOur results suggest that genetic variations in two genes encoding members of the MMP7 and MMP8 are not associated with a risk of BCa in the Caucasian population.

show abstract

Section: Discussionmentioning

confidence: 99%

MMP7 and MMP8 genetic polymorphisms in bladder cancer patients

Wieczorek

Reszka

Wąsowicz

et al. 2013

CEJU

View full text Add to dashboard Cite

show abstract

“…In human samples, total MMP9 activity was significantly higher in malignant breast cancers than in benign breast tumors [6], and circulating MMP9 levels from breast cancer patients were significantly higher than serum levels in women with benign breast disease or healthy controls [7,8]. In fact, reports of MMPs in breast cancer tissue and serum samples have been consistently reported to be increased, and so a recent review called for continued and expanded evaluation of MMPs and hormone-related cancers [9]. …”

Section: Introductionmentioning

confidence: 99%

MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study

Beeghly–Fadiel

Lü

Shu

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose In addition to tumor invasion and angiogenesis, matrix metalloproteinase (MMP)9 also contributes to carcinogenesis and tumor growth. Genetic variation that may influence MMP9 expression was evaluated among participants of the Shanghai Breast Cancer Genetics Study (SBCGS) for associations with breast cancer susceptibility. Methods In stage 1, 11 MMP9 SNPs were genotyped by the Affymetrix Targeted Genotyping System and/or the Affymetrix Genome-Wide Human SNP Array 6.0 among 4,227 SBCGS participants. One SNP was further genotyped using the Sequenom iPLEX MassARRAY platform among an additional 6,270 SBCGS participants. Associations with breast cancer risk were evaluated by odds ratios (OR) and 95% confidence intervals (CI) from logistic regression models that included adjustment for age, education, and genotyping stage when appropriate. Results In Stage 1, rare allele homozygotes for a promoter SNP (rs3918241) or a non-synonymous SNP (rs2274756, R668Q) tended to occur more frequently among breast cancer cases (p-value = 0.116 and 0.056, respectively). Given their high linkage disequilibrium (D′=1.0, r2=0.97), one (rs3918241) was selected for additional analysis. An association with breast cancer risk was not supported by additional Stage 2 genotyping. In combined analysis, no elevated risk of breast cancer among homozygotes was found (OR: 1.2, 95% CI: 0.8–1.8). Conclusions Common genetic variation in MMP9 was not found to be significantly associated with altered breast cancer susceptibility among participants of the Shanghai Breast Cancer Genetics Study.

show abstract

“…These promoter polymorphisms have been associated with susceptibility to diseases, such as rheumatoid arthritis (18), primary sclerosing cholangitis (19), plaque psoriasis (20), and endometriosis (21,22). Investigations of polymorphism in the MMP family also revealed the association of MMP-1, MMP-2, MMP-3, MMP-7 and MMP-9 and some hormone related cancers (29). Investigations of polymorphism in the MMP family also revealed the association of MMP-1, MMP-2, MMP-3, MMP-7 and MMP-9 and some hormone related cancers (29).…”

Section: Introductionmentioning

confidence: 99%